Literature DB >> 6459237

Hormone therapy in advanced breast cancer: high dose medroxyprogesterone acetate (MAP) vs tamoxifen (TMX). Preliminary results.

F Pannuti, A Martoni, F Fruet, E Strocchi, A R Di Marco.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6459237

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0014-2964            Impact factor:   9.162


× No keyword cloud information.
  2 in total

1.  On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancer.

Authors:  E Petru; D Schmähl
Journal:  Klin Wochenschr       Date:  1987-10-15

2.  Medroxyprogesterone acetate (MAP) plasma levels after simultaneous oral and intramuscular administration in cancer patients.

Authors:  F Pannuti; C M Camaggi; E Strocchi; M Giovannini; N Canova; G Murari
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.